Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma
ConditionPancreas Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitut Bergonié
About this trial
This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and/or metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Indication for biopsy of metastasis(es) performed as part of standard care for patients who already have a histologically confirmed diagnosis of pancreatic cancer.
Indication for pancreatic surgery or metastasis(es) carried out as part of standard care for patients with a suspicion of pancreatic cancer on radiological assessment or who already have a confirmed histological diagnosis of pancreatic cancer.
Whatever the stage of the disease.
Disqualifiers
Indication for biopsy for primary diagnosis of pancreatic cancer
No indication for treatment of pancreatic cancer.
Adjuvant/neoadjuvant chemotherapy completed less than 6 months ago in the case of patients with recurrent disease.
Patient already included in the study.
Trial design
Treatments tested in this trial
- Blood sample
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov